Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection by Landovitz, Raphael J. et al.
Phase II Study of Vicriviroc versus Efavirenz (both
with Zidovudine/Lamivudine) in Treatment-Naive
Subjects with HIV-1 Infection
Raphael J. Landovitz,1,a Jonathan B. Angel,2 Christian Hoffmann,3 Heinz Horst,3 Milos Opravil,5 Jianmin Long,1
Wayne Greaves,1 and Gerd Fätkenheuer4
1Schering-Plough Research Institute, Kenilworth, New Jersey; 2Department of Medicine, University of Ottawa, Ottawa, Canada; 3Second
Department of Medicine, University of Schleswig-Holstein, Campus Kiel, and 4Department 1 of Internal Medicine, University of Cologne, Cologne,
Germany; and 5Division of Infectious Diseases, University Hospital Zurich, Zurich, Switzerland
Background. Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency
virus (HIV) replication in vitro and in vivo. We report the results of a phase II dose-finding study of VCV plus dual
nucleoside reverse-transcriptase inhibitors (NRTIs) in the treatment-naive HIV-1–infected subjects.
Methods. This study was a randomized, double-blind, placebo-controlled trial that began with a 14-day com-
parison of 3 dosages of VCVwith placebo in treatment-naive subjects infected with CCR5-usingHIV-1. After 14 days
of monotherapy, lamivudine/zidovudine was added to the VCV arms; subjects receiving placebo were treated with
efavirenz and lamivudine/zidovudine; the planned treatment duration was 48 weeks.
Results. Ninety-two subjects enrolled. After 14 days of once-daily monotherapy, the mean viral loads decreased
frombaseline values by 0.07 log10 copies/mL in the placebo arm, 0.93 log10 copies/mL in theVCV25mg arm, 1.18 log10
copies/mL in the VCV 50 mg arm, and 1.34 log10 copies/mL in the VCV 75 mg arm (P  .001 for each VCV arm vs.
the placebo arm). The combination-therapy portion of the study was stopped because of increased rates of virologic
failure in the VCV 25mg/day arm (relative hazard [RH], 21.6; 95% confidence interval [CI], 2.8–168.9) and the VCV
50 mg/day arm (RH, 11.7; 95% CI, 1.5–92.9), compared with that in the control arm.
Conclusions. VCV administered with dual NRTIs in treatment-naive subjects with HIV-1 infection had in-
creased rates of virologic failure, compared with efavirenz plus dual NRTIs. No treatment-limiting toxicity was
observed. Study of higher doses of VCV as part of combination therapy is warranted.
Increasing rates of resistance, long-term metabolic and
end-organ toxicities are driving factors in the develop-
ment of novel agents and regimens for HIV-infected
treatment-naive persons [1–9].
C-C motif chemokine receptor 5 (CCR5) is one of 2
clinically important coreceptors used by HIV during
CD4 cell entry. CCR5-using (i.e., R5) virus predomi-
nates early in infection, with80% of subjects harbor-
ing subtype B virus exhibiting CCR5 use exclusively
[10–12]. CCR5 has been a target for HIV therapeutics
since the observation that congenital absence confers re-
sistance to infection with minimal clinical sequellae [13,
14]. Moreover, CCR532 heterozygotes have evidence
of slowed HIV disease progression [15–17].
Received 20 December 2007; accepted 1 May 2008; electronically published XX
August 2008.
Potential conflicts of interest: R.J.L. has been a speaker for Abbott and was an
employee of Schering-Plough at the time of study conduct; J.B.A. reports doing
contract research for, acting as an advisor for, giving talks for, and/or receiving
support to attend conferences from GlaxoSmithKline, Bristol-Myers Squibb, Pfizer,
Schering-Plough, Tibotec, Merck, Abbott, Gilead, and Roche; C.H. has been a
consultant to and on the speaker’s bureau for Schering-Plough, Essex, Pfizer,
Gilead, and GlaxoSmithKline; H.H. has received research grants from Gilead, Pfizer,
Merck, and Schering-Plough; M.O. has received research grants, speaker’s and/or
advisory board honoraria, and/or travel grants from Abbott, Boehringer Ingelheim,
Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Pfizer, Roche, and Tibotec;
J.L. and W.G. are employees of Schering-Plough; G.F. has received grants from
Abbott, Gilead, and Roche, has received lecture fees from Abbott, Boehringer-
Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Novartis, Pfizer, Roche,
Schering-Plough, and Tibotec, and has served on advisory boards for Cubist,
Gilead, GlaxoSmithKline, Pfizer, Roche, and Schering-Plough.
The Journal of Infectious Diseases 2008; 198:xxx
© 2008 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2008/19808-00XX$15.00
DOI: 10.1086/592052
Presented in part: 13th Conference on Retroviruses and Opportunistic Infections,
Denver, Colorado, 5–8 February 2006 (abstract 161LB).
Financial support: Schering-Plough Research Institute.
a Current affiliation: Center for Clinical AIDS Research & Education and David
Geffen School of Medicine, University of California, Los Angeles.
Reprints or correspondence: Dr. Raphael Landovitz, 9911 W. Pico Bldv., Ste.
980, Los Angeles, CA 90035 (rlandovitz@mednet.ucla.edu).
M A J O R A R T I C L E
VCV plus 3TC/ZDV in Treatment-Naive Subjects ● JID 2008:198 (15 October) ● 1
Theoretically, the use of CCR5 antagonists may select for
CXCR4-using (i.e., X4) viral populations, which have been as-
sociated with rapid disease progression [18]. Whether emer-
gence of X4 virus accelerates disease progression or is a manifes-
tation of advancing disease is unclear [19–21]. Vicriviroc (VCV
[SCH-D, SCH 417690]) is a small-molecule antagonist of CCR5
that is potent at nanomolar concentrations, is highly specific for
the primate CCR5 receptor, and has excellent oral bioavailability
with minimal preclinical evidence of cardiac toxicity [22–24].
In a phase 1 study involving HIV-infected treatment-naive
subjects, VCV monotherapy was associated with a decrease of
1.6 log10HIVRNA copies/mL at 14 days andwas found to be safe
at twice-daily doses of 10 mg, 25 mg, and 50 mg [24]. Given the
linear and predictable pharmacokinetic profile of VCV and its
mean half-life of 16–17 h, once-daily dosing was selected for
further evaluation.
SUBJECTS, MATERIALS, AND METHODS
Study design. This was a phase II, randomized, double-blind,
placebo-controlled, multicenter study designed to evaluate the
efficacy of 3 once-daily doses of VCV in treatment-naive subjects
infected with R5 virus. Subjects were excluded if they had re-
ceived antiretroviral therapy (ART) for a cumulative duration of
2weeks, if they had ever had X4 or dual/mixed virus (i.e., virus
capable of using CCR5 and/or CXCR4; hereafter, “DM virus”)
recovered, or if they had received ART during the 2-month pe-
riod before randomization.
After screening, eligible subjects were randomized 1:1:1:1 to
receive double-blinded, once-daily VCV (25 mg, 50 mg, or 75
mg)monotherapy or placebo for 14 days.During the subsequent
46-week combination-therapy phase, subjects in the VCV arms
continued to receive VCV treatment and lamivudine/zidovu-
dine (3TC/ZDV) twice daily was added, whereas subjects in the
placebo arm received open-label efavirenz (EFV) 600 mg daily
plus 3TC/ZDV twice daily.
Discontinuation of treatment because of virologic failure was
mandated if 1 of the following criteria were met: the HIV-1
RNA load was confirmed by retesting to have decreased by1.0
log10 copies/mL between baseline and week 4, the HIV-1 RNA
load was confirmed by retesting to be 400 copies/mL on or
after week 20, theHIV-1RNA loadwas confirmed by retesting to
have become detectable (defined as a load of 400 copies/mL)
after a period of undetectability, and/or DM or X4 virus was
detected. During the combination-therapy phase, subjects who
developed treatment-limiting toxicity or intolerance were al-
lowed tomake within-class substitutions (stavudine and nevira-
pine were provided for treatment-limiting toxicity due to ZDV
and EFV, respectively; no substitution was provided for intoler-
ance to VCV). Subjects who experienced virologic failure were
discontinued from the study and treated according to standard
local HIV therapy guidelines, under direction of treating physi-
cians.
Study population. The study population comprised anti-
retroviral-naive HIV-infected adults (age, 18 years) with a
plasmaHIV-1 RNA level of5000 copies/mL, as determined by
the Amplicor HIV-1Monitor test, version 1.5 (RocheMolecular
Systems), and a CD4 cell count of150 cells/mm3. HIV-1 from
all subjects was tested for phenotypic susceptibility to VCV (de-
fined in terms of themaximumpercentage inhibition [MPI] and
the IC50) and for tropism. Subjects were excluded from the study
if DM or X4 virus was detected by the PhenoSense Entry assay
(currently marketed as Trofile [Monogram Biosciences] [25]).
Other exclusion criteria included seizure disorder, evidence of
seizure-predisposing conditions in the central nervous system,
hepatitis C virus coinfection with active viremia, hepatitis B vi-
rus coinfection with circulating surface antigen, and pregnancy
or breast-feeding. Subjects with baseline genotypic evidence of
resistance to EFV, 3TC, or ZDV were excluded. Voluntary writ-
ten informed consent was obtained from all subjects. Institu-
tional reviewboards at each site approved the study protocol and
documents.
Study procedures. Study visits occurred weekly during the
first 4weeks of treatment, at 4-week intervals duringweeks 5–24,
and at 8-week intervals during weeks 25–48. CD4 cell counts
were measured at weeks 2, 4, 12, 20, 24, 32, 40, and 48. Corecep-
tor tropismand susceptibility toVCVweremeasured at baseline,
day 1, day 14, week 24, week 48, and at the time of virologic
failure or early treatment discontinuation. VCV levels were as-
sessed for population pharmacokinetic analysis at the time of
virologic failure and for all subjects remaining on study at the
time of discontinuation of the VCV 25 mg arm.
Pregnancy testing was performed for women at baseline and
day 1 and was repeated if pregnancy was suspected. CCR532
genotype was assayed at baseline, and CCR5 mRNA expression
was measured at baseline and at day 14 for subjects who con-
sented to genetic testing. Adherence to therapy wasmeasured by
pill counts and patient report at each visit.
Information on adverse events and clinical characteristics was
collected at each visit. Adverse events were graded according to
the toxicity grading scale of the AIDS Clinical Trials Group
(available at: http://www3.niaid.nih.gov/research/resources/
DAIDSclinicalresearch/PDF/safety/DAIDSAEGradingTable
.pdf). An independent data safety monitoring board (DSMB)
monitored the progress and results of the study.
Subjects whomet criteria for virologic failure, had treatment-
limiting adverse events despite allowable drug substitution, or
had DM or X4 virus were discontinued from the study. Investi-
gators were provided data on genotypic and phenotypic resis-
tance (determined by means of the PhenoSense assay [Mono-
gram BioSciences]), coreceptor use, and VCV susceptibility in
order to optimize subsequent treatment.
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mRNA analysis. Peripheral blood was collected in special-
ized tubes (PAXgene), and RNA was prepared according to the
manufacturer’s instructions. The quantity and quality of
isolated RNA was analyzed using RNA nano chips (Agilent
Technologies). TaqMan primers and probes were designed with
Universal Probe Library Assay Design software (Roche). Quan-
titative polymerase chain reaction (PCR)was performedwith an
ABI Prism7900HTSequenceDetection System (Applied Biosys-
tems). PCR reactions were prepared using the components from
the iScript Custom One-Step reverse transcription (RT)–PCR
kit with ROX and assembled according to the manufacturer’s
instructions (Bio-Rad). Final concentrations of primers and
probes were 200 nmol/L and 100 nmol/L, respectively. Probes
were labeled with 6-carboxyfluorescein. Each 10-L PCR reac-
tion contained 2 L (20 ng) of RNA. RT-PCR reactions were
performed in triplicate in a 384-well plate. A eukaryotic 18S
rRNA endogenous control probe/primer set (ABI) was used as
an internal control for RNA quality. PCR data were quantitated
using a 12-point standard curve generated by means of 4-fold
serial dilutions of a cDNA containing the gene of interest. CCR5
expression was normalized to 18S RNA levels.
Statistical analysis. All analyses were based on the modi-
fied intent-to-treat (ITT) principle (i.e., data for all randomized
subjects who received at least 1 dose of a study drug were in-
cluded). The primary study end point was the mean change in
the log10 HIV-1 RNA load from baseline to day 14.
Changes frombaselineHIV-1 RNA loads andCD4 cell counts
were analyzed using an analysis of variance (ANOVA) model
with treatment as the covariate. For subjects with a missing
HIV-1 RNA or CD4 cell measurement, the last observation
made after baseline was carried forward. The Fisher exact test
was used to compare proportions of subjects for whom the
HIV-1 RNA load changed by at least 1.0 log10 copies/mL, those
who maintained an HIV-1 RNA load of 50 copies/mL, and
those who maintained an HIV-1 RNA load of400 copies/mL.
Kaplan-Meier analysis was used to investigate the time to viro-
logic failure, and treatment arms were compared using the log-
rank test. Cox proportional hazards modeling was used to com-
pare event rates. Association between the reduction in theHIV-1
RNA load by day 14 and long-term response or virologic failure
among subjects receiving VCV was also explored using logistic
regression. Analyses were conducted using SAS, version 8 (SAS
Institute). Analysis of CCR5 expression was performed using
Graphpad Prizm, and mean values were compared using the
Student t test and ANOVA. The study was planned to ensure
90% power to detect a difference of 1.0 log10 copies/mL from the
baseline HIV-1 RNA load between the VCV 75 mg arm and the
placebo arm, assuming a standard deviation of 0.7 log10 copies/
mL.
RESULTS
Ninety-two subjects entered the study between July 2004 and
May 2005. Eighty percent were male, and 86% were white. The
median baseline CD4 cell count was 290 cells/mm3, and the me-
dian HIV-1 RNA load was 4.79 log10 copies/mL; 36% of subjects
had a baseline HIV-1 RNA load of 100,000 copies/mL. Base-
line characteristics were balanced across treatment groups (table
1). Sixty-three subjects had samples suitable for CCR532
mutation assessment. Eight subjects were heterozygous for
CCR532, and the remaining 55 were homozygous for the wild-
type allele.




Vicriviroc arm, by dosage
Placebo/
EFV control







Age, median (IQR), years 37 (33–41) 37 (33–42) 36 (31–41) 37 (33–40) 38.5 (33–42.5)
Female sex 18 (20) 5 (23) 2 (9) 7 (30) 4 (17)
Race
White 79 (86) 21 (91) 21 (95) 16 (70) 21 (88)
Black 11 (12) 2 (9) 0 6 (26) 3 (13)
Other 2 (2) 0 1 (5) 1 (4) 0
Ethnicity
Latino 15 (16) 6 (26) 4 (18) 2 (9) 3 (13)
Non-Latino 77 (84) 17 (74) 18 (82) 21 (91) 21 (88)
HIV-1 RNA loada
Median (IQR), log10 copies/mL 4.79 (4.39–5.12) 4.78 (4.45–5.03) 4.92 (4.43–5.12) 4.80 (4.27–5.12) 4.70 (4.46–5.19)
100,000 copies/mL 33 (36) 6 (26) 9 (41) 8 (35) 10 (42)
100,000 copies/mL 59 (64) 17 (74) 13 (59) 15 (65) 14 (58)
CD4 cell count,a median (IQR), cells/mm3 290 (231–347) 286 (246–334) 292 (229–322) 295 (239–371) 286 (214–363)
NOTE. Data are no. (%) of study subjects, unless otherwise indicated. IQR, interquartile range; QD, once daily.
a Comparisons between study arms were made by analysis of variance and the Kruskall-Wallis test. No P values were statistically significant.
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Subject disposition at conclusion of monotherapy. One
subject receiving VCV monotherapy was lost to follow-up.
Ninety-one subjects completed the monotherapy phase. Eighty-
eight subjects (97%) entered the combination-therapy phase.
Three subjects receiving placebo elected not to continue into the
combination phase.
HIV-1 RNA response at day 14. The mean decrease in the
HIV-1 RNA load from baseline to day 14 was 0.93 log10 cop-
ies/mL for theVCV25mg arm, 1.18 log10 copies/mL for theVCV
50 mg arm, 1.34 log10 copies/mL for the VCV 75 mg arm, and
0.07 log10 copies/mL for the placebo arm (P  .001 for each
VCV arm vs. the placebo arm, by modified ITT analysis) (figure
1A).
Interim analyses: combination-therapy phase. A planned
DSMB review at the time of primary end point completion by all
subjects noted a trend toward increased rates of persistent vire-
mia of50 copies/mL in the VCV arms and recommended that
all study arms continue to receive therapy. All subsequent deci-
sions were made on the basis of the more rigorous 50 copies/mL
threshold for virologic failure. Follow-up review 4 weeks later
demonstrated that the rate of virologic failure in the VCV 25mg
arm was greater than that in the control arm (relative hazard
[RH], 21.6; 95% confidence interval [CI], 2.8–168.9). The
DSMB recommended that the VCV 25 mg arm be terminated.
Treatment for all subjects in this armwas unblinded and discon-
tinued regardless of viral load suppression status, and CD4 cell
and HIV-1 RNA findings were censored. The median treatment
duration at the time of arm discontinuation was 24.4 weeks
(range, 7.9–53.4 weeks). The DSMB recommended that the
VCV 50 mg and 75 mg arms continue with ongoing monthly
monitoring. In subsequent follow-up analysis, the board noted
that the rates of virologic failure in the VCV 50 mg arm (RH,
11.7; 95% CI, 1.5–92.9) and the pooled 50 mg and 75 mg arms
(RH, 7.8; 95%CI, 1.0–59.9) were greater than that in the control
arm and recommended study termination. The sponsor con-
curred and terminated the study. At the time of termination, the
rate of virologic failure in the VCV 75 mg arm was not statisti-
cally different from that in the control arm (table 2). Themedian
durations of treatment at the time of discontinuation were 32.7
weeks (range, 1.1–57.4weeks) in theVCV50mg arm, 36.3weeks
(range, 6.3–59.0 weeks) in the VCV 75 mg arm, and 35.8 weeks
(duration, 2.0–50.0 weeks) in the control arm. All subjects dis-
continued studymedication at the time of study closure.Data on
CD4 cell counts and viral loads were censored upon discontin-
uation, and subsequent treatment was pursued at the investiga-
tor’s discretion. Virologic decay curves for all subjects are de-
picted in figure 1B. At study termination, the times to failure
were shorter in the VCV 25mg arm (P  .001) and VCV 50mg
arm (P  .003) but not the VCV 75 mg arm (P  .140), com-
pared with the control arm (figure 2).
Of the 88 treated subjects in the combination-therapy phase,
14 (17%) completed 48 weeks of treatment. Treatment was not
completed because of study termination (for 54 subjects [61%]),
virologic failure (for 18 [20%]), an adverse event (for 1 [1%]),
and withdrawal of consent (for 1 [1%]).
Immunologic and virologic response. At week 24, all treat-
ment groups achieved sizable increases inmeanCD4 cell counts;
these changes were not significantly different between treatment
groups (table 2). The mean reduction in the HIV-1 RNA load
between baseline andweek 24was smaller in theVCV25mg arm
(2.43 log10 copies/mL; P  .003) and 75mg arm (2.65 log10 cop-
ies/mL; P  .02), compared with the EFV control arm (3.20
log10 copies/mL).
Adherence. Adherence rates were calculated as the percent-
age of days during the treatment period that were covered by
drug exposure, using pill counts and patient self-reports. All
subjects reported 100% adherence during the monotherapy
phase. During the combination-therapy phase, adherence rates
were98.6%.
Changes in coreceptor use. X4 virus emerged in 8 subjects
(DM virus was detected in 7, and X4 virus was detected in 1).
Three of the 8 observed changes in tropism occurred in the pla-
cebo group without exposure to VCV (all involved DM virus), 1
was observed in the VCV 25 mg group (DM virus), and 4 were
observed in the VCV 75 mg group (3 involved DM virus, and 1
involved X4 virus). Most (6 of 8) tropism changes were detected
on or before day 14, including the emergence of X4 virus.
Two of 3 subjects with non-R5 virus by day 14 who were re-
ceiving VCV, including the subject with X4 virus, experienced
no suppression of viral load during themonotherapy period. For
2 subjects in whom changes in coreceptor use were not observed
until week 24, the HIV-1 RNA load decreased by1 log10 cop-
ies/mL and the CD4 cell count increased by 150 CD4 cells/
mm3 at the time of DM detection (table 3).
Pharmacokinetics. The pharmacokinetic variables Cmin
(trough plasma concentration), Cmax (peak plasma concentra-
tion), and AUC (area under the curve) increased linearly with
the VCVdose andwere consistent with predictions fromphase 1
studies (table 4). Cmin appeared to correlate with a reduction in
the log10 viral load at day 14 (figure 3). Analyses that adjusted for
VCV dose revealed that subjects who experienced virologic fail-
ure during receipt of combination therapy had lower mean Cmin
values (43.2 vs. 66.2 mg/mL; P  .08 for log-transformed com-
parison) and lower mean AUC values (1896.9 vs. 2788.3 ngh/
mL; P  .14 for log-transformed comparison) on day 14, com-
pared with subjects who did not experience virologic failure.
mRNA expression. mRNA samples from whole blood ob-
tained before the study and on day 14 were available for 13 sub-
jects. No difference was observed in mean CCR5 mRNA levels,
normalized for 18SRNA, between day 14 and pretreatment sam-
ples taken at baseline. This was consistent among subjects
treated with VCV (3.70 vs. 3.26; P  .59), among subjects who
received placebo (3.60 vs. 3.17;P  .07), and between treatment
groups at either time point (P  .97).
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Resistance. Of the 26 subjects in the VCV arms who expe-
rienced virologic failure, 22 had evaluable HIV-1 genotypes at
the time of virologic failure. All of the obtainable genotypes
demonstrated the M184V, M184I, or M184V/I mutation, con-
sistent with treatment-emergent 3TC resistance. HIV-1 from
1 subject additionally had the M41L mutation. No other
treatment-emergent genotypic mutations were observed in the
reverse transcriptase gene.
Figure 1. A, Change in log10 HIV-1 RNA load in the modified intent-to-treat population of subjects who received vicriviroc (VCV) or placebo/efavirenz
(EFV). Space does not permit identification of the plotted data points on day 4 of treatment, which represent sample sizes of 16, 21, 19, and 17 subjects,
respectively for the VCV 25 mg, VCV 50 mg, VCV 75 mg, and placebo arms. B, Viral load decay plots for individual subjects, by treatment arm. Subjects
with virologic failure (defined as achievement of an HIV-1 RNA load of 50 copies/mL on or after week 20) are shown in black (on-treatment observed
data only).
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Subjects who went on to experience virologic failure had a
mean VCV IC50 of 6.97 nmol/L and a mean MPI of 96.02%;
values were not significantly different from those for subjects
who did not have virologic failure (6.61 nmol/L [P  .78] and
95.95% [P  .91], respectively). Between baseline and the time
of virologic failure, the mean MPI decreased (96.02% vs.
90.88%; P  .015) but the IC50 was not significantly different
(6.97 vs. 7.11 nmol/L; P  .91). The change in the mean MPI
from baseline to day 14 was 0.4% (95% CI, 1.6% to 0.8%)
among all VCV-treated subjects and1.18% (95% CI,2.91%
to 0.55%) among subjects who went on to experience virologic
failure.
Adverse events. Stavudine was substituted for ZDV in 2
(2%) of 91 subjects because of toxicity; 1 additional subject had
a history of ZDV-related nausea and began combination-phase
treatment with stavudine/3TC. Nevirapine was substituted for
EFV in 3 (13%) of 24 subjects in the control arm because of
central nervous system or cutaneous toxicity. During the treat-
ment period, grade 3 adverse events were observed in 2 subjects
treated with VCV (1 subject with sinusitis and pyrexia in the
VCV 25 mg arm and 1 subject with exacerbation of anal condy-
loma and depression with suicidal ideation in the VCV 75 mg
arm) and in 1 subject in the control arm (major depression).
Grade 4 anemia requiring hospitalization and transfusion oc-
curred in 1 subject taking VCV 50 mg plus 3TC/ZDV. One sub-
ject discontinued treatment because of severe nausea and vom-
iting; the subject was taking VCV 75 mg plus 3TC/ZDV.
No seizures were observed during the study. One exacerba-
tion of preexisting Kaposi sarcoma was observed in the control
arm, concomitant with immune reconstitution. No grade 3 or 4
increases in liver transaminase levels were observed. A single
subject with a normal bilirubin level at study entry developed a
transient grade 3 elevated bilirubin level without clinical or other
laboratory sequellae. The subject continued to receive study
medication, and the bilirubin level decreased to a grade of 2.
Adverse events observed at a rate of 10% among subjects re-
Table 2. Immunologic and virologic outcomes of subjects in the modified intent-to-treat population.
Outcome
Vicriviroc arm, by dosagea Placebo/
EFV control
arm25 mg QD P 50 mg QD P 75 mg QD P
n  23 n  22 n  23 n  24
Increase in CD4 cell count from
baseline to day 14, mean
 SD, cells/mm3 24  88 NS 85 57 .001 90  70 .001 3  66
Decrease in HIV-1 RNA load
from baseline to day 14,
mean  SD, log10 copies/
mL 0.93  0.43 .001 1.18  0.63 .001 1.34  0.64 .001 0.07  0.30
Virologic failureb as defined by
HIV-1 RNA load
400 copies/mL 9 (39) .001 2 (9) NS 3 (13) NS 0
50 copies/mL 13 (56) .001 9 (41) .003 4 (17) NS 1 (4)
Achieved 50 copies/mL 5 (38) 7 (78) 2 (50) 1 (100)
Never achieved 50 copies/
mL 8 (62) 2 (22) 2 (50) 0
Hazard rate for virologic failure,
events/person-year (95%
CI) 1.35 (0.79–2.30) 0.73 (0.38–1.38) 0.30 (0.12–0.77) 0.07 (0.01–0.39)
Relative hazard for virologic
failure (95% CI)c 21.6 (2.8–168.9) 11.7 (1.5–92.9) 4.6 (0.5–41.4) . . .
n  14 n  16 n  16 n  16
Increase in CD4 cell count from
baseline to week 24,
mean  SD, cells/mm3 73  141 NS 110 103 NS 158  171 NS 102  102
Decrease in HIV-1 RNA load
from baseline to week 24,
mean  SD, log10 copies/
mL 2.43  0.65 .003 2.93  0.63 NS 2.65 0.80 .02 3.20 0.57
NOTE. Data are number (%) of subjects, unless otherwise indicated. CI, confidence interval; EFV, efavirenz; NS, not significant; QD, once daily.
a All P values are for comparisons with the placebo/EFV control arm.
b Defined as 1 or more of the following criteria: failure to achieve a reduction of 1 log10 copies/mL in the HIV-1 RNA load by week 4, achievement of an HIV-1
RNA load of 400 or 50 copies/mL after week 20, and/or achievement of an HIV-1 RNA load of 400 or 50 copies/mL (depending on the definition used in
criterion 2) after the load decreased to 400 or 50 copies/mL, respectively.
c Determined by means of a Cox proportional hazards model.
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ceiving VCV at any dose included nausea, fatigue, headache, di-
arrhea, nasopharyngitis, upper abdominal pain, anorexia, dizzi-
ness, and vomiting. None of these rates of adverse events were
significantly different from those in the control group.
DISCUSSION
Despite initial robust decreases in the HIV-1 RNA loads and
increases in CD4 cell counts in all VCV arms during the 2-week
monotherapy lead-in period, persistent or recurrent detectable
viremia was found in the combination-therapy arms containing
lower-dose VCV and prompted early termination of the study.
Subjects with virologic failure appeared to segregate into 2 sub-
sets: those experiencing virologic failure coincident with a shift
in coreceptor tropism use and those with virologic failure in the
absence of a tropism shift. Antiretroviral adherence, asmeasured
by pill count and patient self-report, did not account for the
virologic failures.
Figure 2. Kaplan-Meier estimates of times-to-virologic failure, defined as achievement of an HIV-1 RNA load of 50 copies/mL on or after week
20, among subjects who received vicriviroc (VCV) or placebo/efavirenz (EFV). Absolute hazard rates for virologic failure and relative hazards are listed
in table 2. P values are for pairwise comparisons of each VCV arm with the placebo/EFV arm.
Table 3. Clinical course of 8 subjects in whom HIV-1 using CXCR4 coreceptor only (X4) and HIV-1 capable of using




Baseline value Tropism change
Change from baseline
value to value at













1 Placebo 5.73 270 Day 14 DM 0.28 59
2 Placebo 4.64 302 Day 14 DM 	0.13 	38
3 Placebo 4.57 138 Day 14 DM 	0.10 	29
4 VCV 25 mg 4.72 286 Day 14 DM 0.67 11
5 VCV 75 mg 5.04 308 Day 4 DM 0.09 0
6 VCV 75 mg 4.95 394 Day 14 X4 	0.04 	72
7 VCV 75 mg 4.23 248 Week 24 DM 1.39 	248
8 VCV 75 mg 4.88 188 Week 24 DM 1.89 	161
NOTE. CCR5-using HIV-1 was detected in all subjects at baseline and at the time of screening. VCV, vicriviroc.
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CCR5 receptor antagonists do not appear have significant an-
tiviral activity against DM or X4 virus [26]. In this study, emer-
gence of detectable DMor X4 virus was associated withminimal
viral decay during monotherapy and with emergent resistance
(due to the M184V mutation) during combination therapy,
which is typical of subjects treated with dual nucleoside reverse-
transcriptase inhibitors (NRTIs; 2 of 2 subjects in this study).
Clonal analysis of maraviroc-treated subjects has suggested that
early detection of X4 virus (i.e., by day 14 of treatment) most
likely represents preexisting X4 populations whose sizes at base-
line were less than the threshold of detection for the then-
available assay [27]. More-sensitive assays to assess baseline co-
receptor use may help identify a more R5-homogeneous
treatment population; however, it is increasingly clear that core-
ceptor tropism evolves fluidly both in the presence and absence
of CCR5 antagonist use. In the current study, 3 subjects with R5
virus at screening and baseline had detectable DM virus by day
14 despite only receiving placebo.
In the absence of a change in coreceptor use, a number of
other mechanisms of viral escape can be postulated. IC50 values
do not appear to adequately describe the observed apparent re-
sistance to VCV, consistent with in vitro evidence of on-
treatment selection of strains able to bind and accomplish fusion
and entry via the CCR5-receptor/CCR5-antagonist complex
[28, 29]. Baseline MPIs, more consistent with these mechanistic
observations, also were not associated with virologic failure. De-
creased MPIs were observed at virologic failure, further validat-
ing MPI as the more-relevant resistance measure. Envelope se-
quencing work by others suggests that resistance may be
mediated by critical changes in V3-loop and extra V3-loop se-
quences, distinct from those associated with coreceptor tropism
[30]. Further envelope sequence analyses of subjects with viro-
logic failure are ongoing.
It has been suggested that the 14-day monotherapy pe-
riod generated VCV resistance, leading to increased failure
during combination therapy. This theory is refuted by the








Cmin, median (range), ng/mL 23.8 (11.2–60.2) 44.1 (17.4–102.2) 77.9 (27.2–249.8)
Cmax, median (range), ng/mL 123.6 (65.4–149.4) 245.9 (175.9–373.2) 370 (207.7–495.3)
AUC, median (range), ngh/mL 1095 (682.3–1853) 2104 (1560–3615) 3545 (2097–8276)
NOTE. AUC, area under the curve; Cmax peak plasma concentration; Cmin, trough plasma concentration.
Figure 3. Change in HIV-1 RNA load from baseline to day 14, by trough concentration (Cmin) of vicriviroc, among subjects who received vicriviroc or
placebo/efavirenz (EFV). Analysis was performed using an Emax model with SAS, version 9.1 (SAS Institute), and PROC NLIN. Emax  1.4649  0.1960
log10 copies/mL. The Cmin required to achieve 50% of Emax was 11.624  6.32 ng/mL.
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nonsignificant mean difference of MPIs between baseline and
day 14.
In vitro evidence suggests that intersubject variability in
CCR5 cell-surface expression may have important implications
for susceptibility to CCR5 inhibitors [31]. CCR5mRNAwas not
significantly changed during themonotherapy phase. The power
of this observation is limited, however, as we did not directly
measure cell-surface CCR5 levels. Preformed vacuolized CCR5
may be externalized to the cell surface in the presence of a CCR5
antagonist and may confound the anticipated correlation be-
tweenCCR5mRNA and cell-surface expression.We also did not
assess CCR5 expression during combination therapy.
CCR5/CXCR4 independence, rarely observed in pathogenic
clinical isolates, has been observed in vitro [32–35] and is not
likely to be a clinically important mode of CCR5 inhibitor es-
cape. Although the precise mechanism of virologic failure re-
mains unclear, the high rate of emergence of the M184V muta-
tion in all virologic failures is indicative of inadequate inhibition
of viral replication as contributed to by VCV as a third agent at
the doses and frequency used in the present study.
Population pharmacokinetic studies performed during post
hoc analysis demonstrated that plasma VCV concentrations
were consistent with those observed in phase 1 studies [24]. Cal-
culatedVCVCmin values appeared to be associatedwith themag-
nitude of 14-day HIV-1 RNA load decline, although maximiza-
tion of the dose-response effect was not clearly seen (figure 3).
VCV was well tolerated, with 1 discontinuation because of an
adverse event (alteredmental status, nausea and vomiting) and 1
grade 4 toxicity (anemia), both thought to be unrelated to VCV.
No significant differences in adverse events, laboratory findings,
electrocardiogram findings, or other safety parameters were ob-
served between study arms. Seizures, QTc prolongation, and
grade 3/4 elevations in transaminase levels were not observed. A
VCV study involving treatment-experienced subjects raised
concerns about oncogenic properties of the CCR5-antagonist
class [36, 37]. No treatment-emergent malignancies were re-
ported in VCV-treated subjects in this study. However, the du-
ration of subject follow-up was shorter, and themedian baseline
CD4 cell counts were higher than those in the treatment-
experienced trial (290 vs. 146 cells/mm3), limiting the robustness
of that observation [38].
Lack of a plateau in the dose response and a wide baseline IC50
variability suggest that higher doses of VCV may be required to
maximize virologic suppression. Reluctance to study higher
doses of VCV, owing to animal seizure activity at levels10-fold
higher than the plasma levels expected and observed in the cur-
rent study, has been tempered by the absence of neurotoxicity in
the clinical database. Additional work has increased confidence
in the safety of higher doses, currently in advanced-phase trials
[39].
In conclusion, this study demonstrated that, at the doses stud-
ied, VCV possesses potent antiviral activity and is associated
with a dose-related increase in CD4 cell count. VCVwas safe and
well tolerated. At once-daily doses of 25mg and 50mg,VCVplus
dual NRTI therapy was not as effective as EFV plus dual NRTI
therapy for viral suppression.Optimization of the role of VCV in
combination antiretroviral therapy and characterization of re-
sistance mechanisms require further study.
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